Challenging immunosuppression treatment in lung transplant recipients with kidney failure
详细信息 查看全文
- 作者：Benjamin A. Hö ; gerlea ; 1 ; Neeraj Kohlia ; 1 ; Kirsty Habibi-Parkera ; Haifa Lystera ; Anna Reeda ; Martin Carbya ; Mohamed Zeriouhb ; Alexander Weymannb ; André ; R. Simonb ; Anton Sabashnikovb ; a.sabashnikov@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Aron-Frederik Popovb ; Simona Soresia
- 关键词：AF ; Arterial fibrillation ; ALG ; Anti-lymphocyte globulin ; ATG ; Anti-thymocyte globulin ; BAX ; Basiliximab ; BSSLTX ; Bilateral sequential single lung transplantation ; CMV ; Cytomegalovirus ; CVVH ; Continuous veno-venous hemofiltration ; DBD ; Donation after brain death ; DCD ; Donation after circulatory death ; OB ; Obliterative bronchiolitis ; CF ; Cystic fibrosis ; CNI ; Calcineurin inhibitor ; COPD ; Chronic obstructive pulmonary disease ; ECMO ; Extracorporeal membrane oxygenation ; eGFR ; estimated Glomerular f
- 刊名：Transplant Immunology
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：35
- 期：Complete
- 页码：18-22
- 全文大小：380 K
文摘
- •
Kidney failure after lung transplantation is a risk factor for chronic kidney disease.
- •
10">Basiliximab is a therapeutical option for kidney failure after lung transplant.
- •
15">Basiliximab should be utilized as a “calcineurin inhibitor-free window”.